Инфекция, вызываемая вирусом гриппа птиц А (H5N1)

Список литературы

Основные статьи

Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus; Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z, et al. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med. 2008;358:261-273.Полный текст  Аннотация

World Health Organization. WHO guidelines for pharmacological management of pandemic (H1N1) 2009 influenza and other influenza viruses. February 2010 [internet publication].Полный текст

World Health Organization. WHO rapid advice guidelines on pharmacological management of humans infected with avian influenza A (H5N1) virus. June 2006 [internet publication].Полный текст

Centers for Disease Control and Prevention. Interim guidance on follow-up of close contacts of persons infected with novel influenza A viruses associated with severe human disease and on the use of antiviral medications for chemoprophylaxis. Apr 2015 [internet publication].Полный текст

World Health Organization. Infection control recommendations for avian influenza in health-care facilities. 2006 [internet publication].Полный текст

Centers for Disease Control and Prevention. Influenza antiviral medications: summary for clinicians. Oct 2020 [internet publication].Полный текст

Статьи, указанные как источники

1. Ungchusak K, Auewarakul P, Dowell SF, et al. Probable person-to-person transmission of avian influenza A (H5N1). N Engl J Med. 2005;352:333-340.Полный текст  Аннотация

2. Wang H, Feng Z, Shu Y, et al. Probable limited person-to-person transmission of highly pathogenic avian influenza A (H5N1) virus in China. Lancet. 2008;371:1427-1434. Аннотация

3. Skowronski DM, Tweed SA, Petric M, et al. Human illness and isolation of low-pathogenicity avian influenza virus of the H7N3 subtype in British Columbia, Canada. J Infect Dis. 2006;193:899-900. Аннотация

4. Peiris M, Yuen KY, Leung CW, et al. Human infection with influenza H9N2. Lancet. 1999;354:916-917. Аннотация

5. Uyeki TM, Chong YH, Katz JM, et al. Lack of evidence for human-to-human transmission of avian influenza A (H9N2) viruses in Hong Kong, China 1999. Emerg Infect Dis. 2002;8:154-159.Полный текст  Аннотация

6. Eurosurveillance editorial team. Avian influenza A/(H7N2) outbreak in the United Kingdom. Euro Surveill. 2007;12:pii=3206.Полный текст  Аннотация

7. Kurtz J, Manvell RJ, Banks J. Avian influenza virus isolated from a woman with conjunctivitis. Lancet. 1996;348:901-902. Аннотация

8. Tweed SA, Skowronski DM, David ST, et al. Human illness from avian influenza H7N3, British Columbia. Emerg Infect Dis. 2004;10:2196-2199.Полный текст  Аннотация

9. Nguyen-Van-Tam JS, Nair P, Acheson P, et al. Outbreak of low pathogenicity H7N3 avian influenza in UK, including associated case of human conjunctivitis. Euro Surveill. 2006;11:pii=2952.Полный текст  Аннотация

10. Pan M, Gao R, Lv Q, et al. Human infection with a novel, highly pathogenic avian influenza A (H5N6) virus: virological and clinical findings. J Infect. 2016;72:52-59. Аннотация

11. Yang ZF, Mok CK, Peiris JS, et al. Human infection with a novel avian influenza A (H5N6) virus. N Engl J Med. 2015;373:487-489.Полный текст  Аннотация

12. World Health Organization/World Organisation for Animal Health/Food and Agriculture Organization H5N1 Evolution Working Group. Revised and updated nomenclature for highly pathogenic avian influenza A (H5N1) viruses. Influenza Other Respir Viruses. 2014;8:384-388.Полный текст  Аннотация

13. World Health Organization. Evolution of the influenza A(H5) haemagglutinin: WHO/OIE/FAO H5 Working Group reports a new clade designated 2.3.4.4. January 2015 [internet publication].Полный текст

14. Smith GJ, Donis RO; World Health Organization/World Organisation for Animal Health/Food and Agriculture Organization (WHO/OIE/FAO) H5 Evolution Working Group. Nomenclature updates resulting from the evolution of avian influenza A(H5) virus clades 2.1.3.2a, 2.2.1, and 2.3.4 during 2013-2014. Influenza Other Respir Viruses. 2015;9:271-276.Полный текст  Аннотация

15. World Health Organization. Antigenic and genetic characteristics of influenza A(H5N1) and influenza A(H9N2) viruses and candidate vaccine viruses developed for potential use in human vaccines: February 2010. Wkly Epidemiol Rec. 2010;85:100-107.Полный текст

16. Nguyen T, Rivailler P, Davis CT, et al. Evolution of highly pathogenic avian influenza (H5N1) virus populations in Vietnam between 2007 and 2010. Virology. 2012;432:405-416. Аннотация

17. Writing Committee of the Second World Health Organization Consultation on Clinical Aspects of Human Infection with Avian Influenza A (H5N1) Virus; Abdel-Ghafar AN, Chotpitayasunondh T, Gao Z, et al. Update on avian influenza A (H5N1) virus infection in humans. N Engl J Med. 2008;358:261-273.Полный текст  Аннотация

18. World Health Organization. Update on human cases of highly pathogenic avian influenza A(H5N1) virus infection, 2010. Wkly Epidemiol Rec. 2011;86:161-166.Полный текст  Аннотация

19. Uyeki TM. Human infection with highly pathogenic avian influenza A (H5N1) virus: review of clinical issues. Clin Infect Dis. 2009;49:279-290.Полный текст  Аннотация

20. de Jong MD, Bach VC, Phan TQ, et al. Fatal avian influenza A (H5N1) in a child presenting with diarrhea followed by coma. N Engl J Med. 2005;352:686-691.Полный текст  Аннотация

21. Rajabali N, Lim T, Sokolowski C, et al. Avian influenza A (H5N1) infection with respiratory failure and meningoencephalitis in a Canadian traveller. Can J Infect Dis Med Microbiol. 2015;26:221-223.Полный текст  Аннотация

22. Kandeel A, Manoncourt S, Abd el Kareem E, et al. Zoonotic transmission of avian influenza virus (H5N1), Egypt, 2006-2009. Emerg Infect Dis. 2010;16:1101-1107.Полный текст  Аннотация

23. International Centre for Diarrhoeal Disease Research, Bangladesh (ICDDR,B). Outbreak of mild respiratory disease caused by H5N1 and H9N2 infections among young children in Dhaka, Bangladesh, 2011. Health Sci Bulletin. 2011;9:1-12.Полный текст

24. Oner AF, Dogan N, Gasimov V, et al. H5N1 avian influenza in children. Clin Infect Dis. 2012;55:26-32.Полный текст  Аннотация

25. Shinde V, Hanshaoworakul W, Simmerman JM, et al. A comparison of clinical and epidemiological characteristics of fatal human infections with H5N1 and human influenza viruses in Thailand, 2004-2006. PLoS One. 2011;6:e14809.Полный текст  Аннотация

26. World Health Organization. Cumulative number of confirmed human cases of avian influenza A(H5N1) reported to WHO. 2018 [internet publication].Полный текст

27. World Health Organization. Information on avian influenza A (H5N1) identified in human in Nepal. May 2019 [internet publication].Полный текст

28. World Health Organization. Avian Influenza A(H5N1)- Lao People's Democratic Republic. Nov 2020 [internet publication].Полный текст

29. World Health Organization. Update: WHO-confirmed human cases of avian influenza A (H5N1) infection, November 2003-May 2008. Wkly Epidemiol Rec. 2008;83:415-420.Полный текст  Аннотация

30. Centers for Disease Control and Prevention. Highly pathogenic Asian avian influenza A (H5N1) virus. May 2018 [internet publication].Полный текст

31. Food and Agriculture Organization of the United Nations. Update on the continuous spread and expansion of H5N1 highly pathogenic avian influenza: clade 2.3.2.1 in Asia (2010-2012). January 2014 [internet publication].Полный текст

32. Qi Y, Ni HB, Chen X, et al. Seroprevalence of highly pathogenic avian influenza (H5N1) virus infection among humans in mainland China: A systematic review and meta-analysis. Transbound Emerg Dis. 2020 Apr 7 [Epub ahead of print]. Аннотация

33. Gomaa MR, El Rifay AS, Abu Zeid D, et al. Incidence and seroprevalence of avian influenza in a cohort of backyard poultry growers, Egypt, August 2015-March 2019. Emerg Infect Dis. 2020 Sep;26(9):2129-36.Полный текст  Аннотация

34. Centers for Disease Control and Prevention. Highly pathogenic avian influenza A (H5N1) in birds and other animals. Jan 2015 [internet publication].Полный текст

35. Tong S, Zhu X, Li Y, et al. New world bats harbor diverse influenza A viruses. PLoS Pathog. 2013;9:e1003657.Полный текст  Аннотация

36. Areechokchai D, Jiraphongsa C, Laosiritaworn Y, et al. Investigation of avian influenza (H5N1) outbreak in humans: Thailand, 2004. MMWR Morb Mortal Wkly Rep. 2006;55(suppl 1):3-6.Полный текст  Аннотация

37. Dinh PN, Long HT, Tien NT, et al. Risk factors for human infection with avian influenza A H5N1, Vietnam, 2004. Emerg Infect Dis. 2006;12:1841-1847.Полный текст  Аннотация

38. World Health Organization. Update on human cases of highly pathogenic avian influenza A(H5N1) virus infection, 2011. WHO Wkly Epidemiolog Rec. 2012;87:117-128.Полный текст

39. Mounts AW, Kwong H, Izurieta HS, et al. Case-control study of risk factors for avian influenza A (H5N1) disease, Hong Kong, 1997. J Infect Dis. 1999;180:505-508. Аннотация

40. Zhou L, Liao Q, Dong L, et al. Risk factors for human illness with avian influenza A (H5N1) virus infection in China. J Infect Dis. 2009;199:1726-1734. Аннотация

41. Wan XF, Dong L, Lan Y, et al. Indications that live poultry markets are a major source of human H5N1 influenza virus infection in China. J Virol. 2011;85:13432-13438.Полный текст  Аннотация

42. Kandun IN, Tresnaningsih E, Purba WH, et al. Factors associated with case fatality of human H5N1 virus infections in Indonesia: a case series. Lancet. 2008;372:744-749. Аннотация

43. Horby P, Sudoyo H, Viprakasit V, et al. What is the evidence of a role for host genetics in susceptibility to influenza A/H5N1? Epidemiol Infect. 2010;138:1550-1558.Полный текст  Аннотация

44. Human cases of avian influenza A (H5N1) in North-West Frontier Province, Pakistan, October-November 2007. Wkly Epidemiol Rec. 2008;83:359-364. Аннотация

45. Aditama TY, Samaan G, Kusriastuti R, et al. Risk factors for cluster outbreaks of avian influenza A H5N1 infection, Indonesia. Clin Infect Dis. 2011;53:1237-1244.Полный текст  Аннотация

46. Aditama TY, Samaan G, Kusriastuti R, et al. Avian influenza H5N1 transmission in households, Indonesia. PLoS One. 2012;7:e29971.Полный текст  Аннотация

47. Kandun IN, Wibisono H, Sedyaningsih ER, et al. Three Indonesian clusters of H5N1 virus infection in 2005. N Engl J Med. 2006;355:2186-2194.Полный текст  Аннотация

48. Beigel JH, Farrar J, Han AM, et al. Avian influenza A (H5N1) infection in humans. N Engl J Med. 2005;353:1374-1385.Полный текст  Аннотация

49. Imai M, Watanabe T, Hatta M, et al. Experimental adaptation of an influenza H5 HA confers respiratory droplet transmission to a reassortant H5 HA/H1N1 virus in ferrets. Nature. 2012;486:420-428.Полный текст  Аннотация

50. Neumann G, Macken CA, Karasin AI, et al. Egyptian H5N1 influenza viruses-cause for concern? PLoS Pathog. 2012;8:e1002932.Полный текст  Аннотация

51. Russell CA, Fonville JM, Brown AE, et al. The potential for respiratory droplet-transmissible A/H5N1 influenza virus to evolve in a mammalian host. Science. 2012;336:1541-1547.Полный текст  Аннотация

52. Uyeki TM, Bresee JS. Detecting human-to-human transmission of avian influenza A (H5N1). Emerg Infect Dis. 2007;13:1969-1971.Полный текст  Аннотация

53. Refaey S, Azziz-Baumgartner E, Amin MM, et al. Increased number of human cases of influenza virus A(H5N1) infection, Egypt, 2014-15. Emerg Infect Dis. 2015;21:2171-2173.Полный текст  Аннотация

54. Le MQ, Horby P, Fox A, et al. Subclinical avian influenza A(H5N1) virus infection in human, Vietnam. Emerg Infect Dis. 2013;19:1674-1677.Полный текст  Аннотация

55. Garten RJ, Davis CT, Russell CA, et al. Antigenic and genetic characteristics of swine-origin 2009 A(H1N1) influenza viruses circulating in humans. Science. 2009;325:197-201.Полный текст  Аннотация

56. Horimoto T, Kawaoka Y. Influenza: lessons from past pandemics, warnings from current incidents. Nat Rev Microbiol. 2005;3:591-600. Аннотация

57. Yamada S, Suzuki Y, Suzuki T, et al. Haemagglutinin mutations responsible for the binding of H5N1 influenza A viruses to human-type receptors. Nature. 2006;444:378-382. Аннотация

58. van Riel D, Munster VJ, de Wit E, et al. H5N1 virus attachment to lower respiratory tract. Science. 2006;312:399.Полный текст  Аннотация

59. Shu Y, Li CK, Li Z, et al. Avian influenza A(H5N1) viruses can directly infect and replicate in human gut tissues. J Infect Dis. 2010;201:1173-1177. Аннотация

60. Chandrasekaran A, Srinivasan A, Raman R, et al. Glycan topology determines human adaptation of avian H5N1 virus hemagglutinin. Nat Biotechnol. 2008;26:107-113. Аннотация

61. Auewarakul P, Suptawiwat O, Kongchanagul A, et al. An avian influenza H5N1 virus that binds to a human-type receptor. J Virol. 2007;81:9950-9955.Полный текст  Аннотация

62. Chan MC, Cheung CY, Chui WH, et al. Proinflammatory cytokine responses induced by influenza A (H5N1) viruses in primary human alveolar and bronchial epithelial cells. Respir Res. 2005;6:135.Полный текст  Аннотация

63. de Jong MD, Simmons CP, Thanh TT, et al. Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia. Nat Med. 2006;12:1203-1207. Аннотация

64. Gu J, Xie Z, Gao Z, et al. H5N1 infection of the respiratory tract and beyond: a molecular pathology study. Lancet. 2007;370:1137-1145. Аннотация

65. Cavailler P, Chu S, Ly S, et al. Seroprevalence of anti-H5 antibody in rural Cambodia, 2007. J Clin Virol. 2010;48:123-126. Аннотация

66. Apisarnthanarak A, Erb S, Stephenson I, et al. Seroprevalence of anti-H5 antibody among Thai health care workers after exposure to avian influenza (H5N1) in a tertiary care center. Clin Infect Dis. 2005;40:e16-e18. Аннотация

67. Liem NT, Lim W. Lack of H5N1 avian influenza transmission to hospital employees, Hanoi, 2004. Emerg Infect Dis. 2005;11:210-215.Полный текст  Аннотация

68. Schultsz C, Dong VC, Chau NV, et al. Avian influenza H5N1 and healthcare workers. Emerg Infect Dis. 2005;11:1158-1159.Полный текст  Аннотация

69. World Health Organization. WHO laboratory biosafety guidelines for handling specimens suspected of containing avian influenza A virus. January 2005 [internet publication].Полный текст

70. Ortiz JR, Katz MA, Mahmoud MN, et al. Lack of evidence of avian-to-human transmission of avian influenza A (H5N1) virus among poultry workers, Kano, Nigeria, 2006. J Infect Dis. 2007;196:1685-1691. Аннотация

71. Prieto-Lara E, Llanos-Mendez A. Safety and immunogenicity of prepandemic H5N1 influenza vaccines: a systematic review of the literature. Vaccine. 2010;28:4328-4334. Аннотация

72. Vesikari T, Forstén A, Herbinger KH, et al. Safety and immunogenicity of an MF59(®)-adjuvanted A/H5N1 pre-pandemic influenza vaccine in adults and the elderly. Vaccine. 2012;30:1388-1396. Аннотация

73. Langley JM, Risi G, Caldwell M, et al. Dose-sparing H5N1 A/Indonesia/05/2005 pre-pandemic influenza vaccine in adults and elderly adults: a phase III, placebo-controlled, randomized study. J Infect Dis. 2011;203:1729-1738.Полный текст  Аннотация

74. US Food and Drug Administration. Influenza virus vaccine, H5N1 (for national stockpile). February 2018 [internet publication].Полный текст

75. Qualls N, Levitt A, Kanade N, et al; CDC Community Mitigation Guidelines Work Group. Community mitigation guidelines to prevent pandemic influenza - United States, 2017. MMWR Recomm Rep. 2017;66:1-34.Полный текст  Аннотация

76. Centers for Disease Control and Prevention. Interim guidance for specimen collection, processing, and testing for patients with suspected infection with novel influenza A viruses associated with severe disease in humans. May 2014 [internet publication].Полный текст

77. World Health Organization. Collecting, preserving and shipping specimens for the diagnosis of avian influenza A(H5N1) virus infection. October 2006 [internet publication].Полный текст

78. World Health Organization. Clinical management of human infection with avian influenza A (H5N1) virus. August 2007 [internet publication].Полный текст

79. World Health Organization. Recommendations and laboratory procedures for detection of avian influenza A(H5N1) virus in specimens from suspected human cases. August 2007 [internet publication].Полный текст

80. World Health Organization. WHO criteria for accepting positive PCR test results of H5 infection in humans from national reference laboratories. May 2011 [internet publication].Полный текст

81. World Health Organization. WHO accepts positive PCR test results of H5 infection in humans from the following laboratories. May 2011 [internet publication].Полный текст

82. World Health Organization. WHO reference laboratories for diagnosis of influenza A/H5 infection. May 2017 [internet publication].Полный текст

83. Powell TJ, Fox A, Peng Y, et al. Identification of H5N1-specific T-cell responses in a high-risk cohort in Vietnam indicates the existence of potential asymptomatic infections. J Infect Dis. 2012;205:20-27. Аннотация

84. American Academy of Pediatrics. Respiratory syncytial virus. In: Pickering LK, ed. Red book: 2006 report of the Committee on Infectious Diseases, 27th ed. Elk Grove Village, IL: American Academy of Pediatrics; 2006:561.

85. Centers for Disease Control and Prevention. Interim guidance on case definitions for investigations of human infection with highly pathogenic avian influenza A (H5N1) virus in the United States. January 2016 [internet publication].Полный текст

86. World Health Organization. WHO case definitions for human infections with influenza A(H5N1) virus. August 2006 [internet publication].Полный текст

87. Schunemann HJ, Hill SR, Kakad M, et al. WHO rapid advice guidelines for pharmacological management of sporadic human infection with avian influenza A (H5N1) virus. Lancet Infect Dis. 2007;7:21-31. Аннотация

88. World Health Organization. WHO guidelines for pharmacological management of pandemic (H1N1) 2009 influenza and other influenza viruses. February 2010 [internet publication].Полный текст

89. World Health Organization. WHO rapid advice guidelines on pharmacological management of humans infected with avian influenza A (H5N1) virus. June 2006 [internet publication].Полный текст

90. Centers for Disease Control and Prevention. Interim guidance on follow-up of close contacts of persons infected with novel influenza A viruses associated with severe human disease and on the use of antiviral medications for chemoprophylaxis. Apr 2015 [internet publication].Полный текст

91. Patel RB, Mathur MB, Gould M, et al. Demographic and clinical predictors of mortality from highly pathogenic avian influenza A (H5N1) virus infection: CART analysis of international cases. PLoS One. 2014;9:e91630.Полный текст  Аннотация

92. Arabi Y, Gomersall CD, Ahmed QA, et al. The critically ill avian influenza A (H5N1) patient. Crit Care Med. 2007;35:1397-1403. Аннотация

93. Adisasmito W, Chan PK, Lee N, et al. Effectiveness of antiviral treatment in human influenza A (H5N1) infections: analysis of a Global Patient Registry. J Infect Dis. 2010;202:1154-1160.Полный текст  Аннотация

94. Chan PK, Lee N, Zaman M, et al. Determinants of antiviral effectiveness in influenza virus A subtype H5N1. J Infect Dis. 2012;206:1359-1366. Аннотация

95. de Jong MD, Tran TT, Truong HK, et al. Oseltamivir resistance during treatment of influenza A (H5N1) infection. N Engl J Med. 2005;353:2667-2672.Полный текст  Аннотация

96. Le QM, Kiso M, Someya K, et al. Avian flu: isolation of drug-resistant H5N1 virus. Nature. 2005;437:1108. Аннотация

97. Le MT, Wertheim HF, Nguyen HD, et al. Influenza A H5N1 clade 2.3.4 virus with a different antiviral susceptibility profile replaced clade 1 virus in humans in northern Vietnam. PLoS One. 2008;3:e3339.Полный текст  Аннотация

98. Duval X, van der Werf S, Blanchon T, et al. Efficacy of oseltamivir-zanamivir combination compared to each monotherapy for seasonal influenza: a randomized placebo-controlled trial. PLoS Med. 2010;7:e1000362.Полный текст  Аннотация

99. World Health Organization. Infection control recommendations for avian influenza in health-care facilities. 2006 [internet publication].Полный текст

100. Centers for Disease Control and Prevention. Influenza antiviral medications: summary for clinicians. Oct 2020 [internet publication].Полный текст

101. American Academy of Pediatrics Committee on Infectious Diseases. Recommendations for prevention and control of influenza in children, 2013-2014. Pediatrics. 2013;132:e1089-e1104.Полный текст  Аннотация

102. Kayali G, Webby RJ, Ducatez MF, et al. The epidemiological and molecular aspects of influenza H5N1 viruses at the human-animal interface in Egypt. PLoS One. 2011;6:e17730.Полный текст  Аннотация

103. Fiebig L, Soyka J, Buda S, et al. Avian influenza A(H5N1) in humans: new insights from a line list of World Health Organization confirmed cases, September 2006 to August 2010. Euro Surveill. 2011;16:19941. Аннотация

104. Taylor WR, Thinh BN, Anh GT, et al. Oseltamivir is adequately absorbed following nasogastric administration to adult patients with severe H5N1 influenza. PLoS One. 2008;3:e3410.Полный текст  Аннотация

105. Zhou B, Zhong N, Guan Y. Treatment with convalescent plasma for influenza A (H5N1) infection. N Engl J Med. 2007;357:1450-1451.Полный текст  Аннотация

106. Yu H, Gao Z, Feng Z, et al. Clinical characteristics of 26 human cases of highly pathogenic avian influenza A (H5N1) virus infection in China. PLoS One. 2008;3:e2985.Полный текст  Аннотация

107. Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al. The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J infect Dis. 2015;211:80-90.Полный текст  Аннотация

108. Ikematsu H, Kawai N. Laninamivir octanoate: a new long-acting neuraminidase inhibitor for the treatment of influenza. Expert Rev Anti Infect Ther. 2011;9:851-857. Аннотация

109. Ilyushina NA, Hay A, Yilmaz N, et al. Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice. Antimicrob Agents Chemother. 2008;52:3889-3897.Полный текст  Аннотация

110. Muller MP, Dresser L, Raboud J, et al. Adverse events associated with high-dose ribavirin: evidence from the Toronto outbreak of severe acute respiratory syndrome. Pharmacotherapy. 2007;27:494-503. Аннотация

111. Lee N, Chan PK, Hui DS, et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J Infect Dis. 2009;200:492-500. Аннотация

112. Han K, Ma H, An X, et al. Early use of glucocorticoids was a risk factor for critical disease and death from pH1N1infection. Clin Infect Dis. 2011;53:326-333. Аннотация

113. Lee CM, Hudson LD. Long-term outcomes after ARDS. Semin Respir Crit Care Med. 2001;22:327-336. Аннотация

114. Ehlenbach WJ, Hough CL, Crane PK, et al. Association between acute care and critical illness hospitalization and cognitive function in older adults. JAMA. 2010;303:763-770.Полный текст  Аннотация

Использование этого контента попадает под действие нашего заявления об отказе от ответственности